See more : Williams-Sonoma, Inc. (WSM) Income Statement Analysis – Financial Results
Complete financial analysis of Advagene Biopharma Co., Ltd. (6709.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Advagene Biopharma Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Credit Corp Group Limited (CCP.AX) Income Statement Analysis – Financial Results
- UVAT Technology Co., Ltd. (3580.TWO) Income Statement Analysis – Financial Results
- F&F Holdings Co., Ltd. (007700.KS) Income Statement Analysis – Financial Results
- SillaJen, Inc. (215600.KQ) Income Statement Analysis – Financial Results
- Nomura Real Estate Master Fund, Inc. (3462.T) Income Statement Analysis – Financial Results
Advagene Biopharma Co., Ltd. (6709.TWO)
About Advagene Biopharma Co., Ltd.
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. Its products in development include nasal spray influenza vaccine, allergy vaccines, and COVID-19 immunotherapy. The company is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 12.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -12.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 73.22M | 100.04M | 72.68M | 55.33M | 70.73M |
| General & Administrative | 20.12M | 19.77M | 21.75M | 20.46M | 28.12M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.12M | 19.77M | 21.75M | 20.46M | 28.12M |
| Other Expenses | 0.00 | 202.00K | 340.00K | 4.04M | 0.00 |
| Operating Expenses | 93.34M | 119.81M | 94.43M | 75.79M | 93.45M |
| Cost & Expenses | 93.34M | 119.81M | 94.43M | 75.79M | 93.45M |
| Interest Income | 1.02M | 1.31M | 1.53M | 1.70M | 0.00 |
| Interest Expense | 36.00K | 81.00K | 127.00K | 107.00K | 0.00 |
| Depreciation & Amortization | 12.00M | 11.60M | 7.73M | 7.89M | 4.56M |
| EBITDA | -80.07M | -106.69M | -84.83M | -62.17M | -94.29M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -93.34M | -118.30M | -92.56M | -70.06M | -98.84M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.23M | 1.43M | 1.74M | 5.63M | 7.23M |
| Income Before Tax | -92.11M | -118.38M | -92.69M | -70.16M | -91.62M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -92.11M | -118.38M | -92.69M | -70.16M | -91.62M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.83 | -2.40 | -1.88 | -1.57 | -2.05 |
| EPS Diluted | -1.83 | -2.40 | -1.88 | -1.57 | -2.05 |
| Weighted Avg Shares Out | 50.39M | 49.32M | 49.18M | 44.73M | 44.60M |
| Weighted Avg Shares Out (Dil) | 50.39M | 49.32M | 49.18M | 44.73M | 44.60M |
No news found for: 6709.TWO
Source: https://incomestatements.info
Category: Stock Reports